Today Ely Lilly (LLY) announced the positive results on a phase 2 diabetes drug of theirs ( LY3298176 ) via a publication in The Lancet, a presentation at the annual meeting of the European Association for the Study of Diabetes (EASD) and the press release below: Lilly's Investigational Dual GIP and GLP-1 Receptor Agonist Shows Significant Reduction in HbA1c and Body Weight in People With Type 2 Diabetes The press release created a few headlines: Bloomberg: Diabetes Drug's Results Push Lilly to Look at Obesity Too Reuters: Lilly's diabetes drug data impresses, hurts rival Novo's shares The share price of Eli Lilly went up by 4% in an otherwise sour market and that of Danish rival Novo Nordisk (NOVO-B.CO) plummeted some 7-8%
Maintenance therapy, using lower stable doses, carries a favorable safety profile
Any patient taking Trulicity should engage in regular monitoring for symptoms
PJ: Conceptualization, Funding acquisition, Resources, Supervision, Writing review & editing
Durham Same-day availability window Raleigh Next-day ground delivery Chapel Hill Next-day ground delivery Cary Next-day ground delivery Morrisville Next-day ground delivery Research Triangle Park (RTP) Same-day availability window Apex 1-2 day ground delivery Wake Forest 1-2 day ground delivery Garner 1-2 day ground delivery Holly Springs 1-2 day ground delivery Fuquay-Varina 1-2 day ground delivery Greensboro 1-2 day ground delivery Winston-Salem 1-2 day ground delivery Charlotte 1-2 day ground delivery Wilmington 2-day ground delivery Asheville 2-day ground delivery North Carolina (statewide) 1-3 day ground delivery Institutional Supply Serving Durham's Research Institutions Dedicated institutional procurement support for Duke University, UNC Chapel Hill, NC Central University, and RTP contract research organizations
To aid my hair regrowth, Im currently taking the Smarty Pants prenatal gummy daily